



1645
P#8

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	April 22, 2002
INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents Washington, D.C. 20231 		Attorney Docket	CHOR-001
		First Named Inventor	Granoff et al.
		Application Number	09/917,222
		Confirmation No.	9605
		Filing Date	July 27, 2001
		Group Art Unit	1645
		Examiner Name	N/A
Title	Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis		

RECEIVED
MAY 08 2002
TECH CENTER 1600/2900

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper except for documents AE, AF, AK, and AM, which are enclosed on a compact disk. Also enclosed please find a copy of the International Search report dated March 25, 2002. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged thereon to order No. CHOR-001.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: April 22, 2002

By: 
Carol L. Francis
Registration No. 36,613

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231
F:\FORMS\Word 2K forms\IDS - before 1st OA.doc

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/917,222
			Filing Date	July 27, 2001
			First Named Inventor	Granoff et al.
			Group Art Unit	1645
			Examiner Name	N/A
Sheet 1 of 4	Attorney Docket Number		CHOR-001	

RECEIVED
MAY 08 2002
MAIL ROOM

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	4,601,903		Frasch	07-22-1986	
	AB	4,727,136		Jennings, et al.	02-23-1988	
	AC	5,705,161		Van Der Ley et al.	01-06-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AD		0 449 958 B1		Seid et al.	03/22/95		
	AE		WO 00/22430		Frazer et al.	04/20/00	(See CD-ROM)	
	AF		WO 00/66791		Pizza et al.	02/09/00	(See CD-ROM)	
	AG		WO 01/09350		Berthet et al.	02/08/01		
	AH		W0 96/29412		Brodeur et al.	09/26/96		
	AI		WO 98/02547		Nassif et al.	01/22/98		
	AJ		WO 98/56901		Baldwin et al.	12/17/98		
	AK		WO 99/24578		Masignani et al.	05/20/99	(See CD-ROM)	
	AL		WO 99/36544		Masignani et al.	07/22/99		
	AM		WO 99/57280		Fraser et al.	04/30/99	(See CD-ROM)	
	AN		WO 99/61053		Granoff et al.	12/02/99		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0654-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/917,222
		Filing Date	July 27, 2001
		First Named Inventor	Granoff et al.
		Group Art Unit	1645
		Examiner Name	N/A
Sheet 2 of 4	Attorney Docket Number	CHOR-001	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AO	ASHTON, F. E. et al., 1938, "A New Serogroup (L) of <i>Neisseria meningitidis</i> ", <i>J. Clin. Microbiol.</i> 17: 722-727.	
	AP	BORROW, et al., 2001, "Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the U.K.: Reevaluation of Correlates of Protection", <i>Infection and Immunity</i> , 69(3):1568-1573.	
	AQ	BRANHAM, S. E., 1956, "Milestones in the History of Meningococcus", <i>Canadian Journal of Microbiology</i> , 2:175-188.	
	AR	CAMPAGNE et al. 2000, "Safety and immunogenicity of three doses of a <i>Neisseria meningitidis</i> A + C diphtheria conjugate vaccine in infants from Niger", <i>Pediatric Infectious Disease Journal</i> , 19(2):144-150.	
	AS	CARTWRIGHT K et al, 1999, "Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins", <i>Vaccine</i> , 17:2612-2619.	
	AT	DE KLEINJN ED et al, 2000, "Immunogenicity and safety of a hexavalent meningococcal outer membrane-vesicle vaccine in children of 2-3 and 7-8 years of age", <i>Vaccine</i> , 18:1456-1466.	
	AU	FRASCH, C. E. AND CHAPMAN, 1973, "Classification of <i>Neisseria meningitidis</i> Group B into Distinct Serotypes. III. Application of a New Bactericidal-Inhibition Technique to Distribution of Serotypes among Cases and Carriers" <i>Journal of Infectious Disease</i> , 127:149-154.	
	AV	FUSCO et al., 1997, "Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in both Mice and Nonhuman Primates", <i>Journal of Infectious Diseases</i> , 175: 364-372.	
	AW	GOLD et al., 1969-1970, "Meningococcal Infections" <i>Bull. WHO</i> , 45: 272-282.	
	AX	GOLDSCHNEIDER et al, 1969, "Human Immunity to the Meningococcus: I. The Role of the Humoral Antibodies" <i>J. Exp. Med.</i> 129:1307-1326.	
	AY	GOTSCHLICH et al., 1969, "Human Immunity to the Meningococcus: III. Preparation and Immunochemical Properties of the Group A, Group B, and Group C Meningococcal Polysaccharides", <i>J. Exp. Med.</i> 129:134-136.	
	AZ	GRANOFF et al., 1998, "Bacterial Monoclonal Antibodies That Define Unique Meningococcal B Polysaccharide Epitopes That Do Not Cross-React with Human Polysialic Acid", <i>J. Immunol.</i> 160: 5028-5036.	
	BA	GRANOFF et al., 1998, "Induction of Immunologic Refractoriness in Adults by Meningococcal C Polysaccharide Vaccination", <i>J. Infect. Dis.</i> 178(3): 870-4.	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (03/00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/917,222
		Filing Date	July 27, 2001
		First Named Inventor	Granoff et al.
		Group Art Unit	1645
		Examiner Name	N/A
Sheet 3 of 4	Attorney Docket Number	CHOR-001	

BB	HANKINS, 1982, "Clinical and Serological Evaluation of a Meningococcal Polysaccharide Vaccine Groups A,C,Y, and W135 (41306), <i>Proc. Soc. Biol. Med.</i> 169: 54-57.
BC	JENNINGS et al., 1981, "Inhibitory Effect of K-76 Monocarboxylic Acid, an Anticomplementary Agent, on the C3b Inactivator System" <i>J Immunol.</i> 127:104-108
BD	MACDONALD et al., 1998, "Induction of Immunologic Memory by Conjugated vs Plain Meningococcal C Polysaccharide Vaccine in Toddlers", <i>JAMA</i> 280:1685-1689
BE	MACDONALD et al., 2000, "*****" <i>JAMA</i> 283:1826-1827
BF	MACLENNAN et al., 2000, "Safety, Immunogenicity, and Induction of Immunologic memory by a Serogroup C Meningococcal Conjugate Vaccine in Infants" <i>JAMA</i> 283: 2795-2801
BG	MAIDEN et al., 1998, "Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms", <i>Proc. Natl. Acad. Sci. USA</i> 95:3140-3145.
BH	MARTIN et al., 2000. "Candidate <i>Neisseria meningitidis</i> NspA vaccine", <i>J. Biotechnol.</i> 83:27-31
BI	MARTIN et al, 2000, "Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine", <i>Vaccine</i> , 18:2476-2481
BJ	MOE et al. 1999, "Differences in Surface Expression of NspA among <i>Neisseria meningitidis</i> Group B Strains", <i>Infection and Immunity</i> , 67:5664-5675.
BK	MOE et al. 2001, "Functional Activity of Anti- <i>Neisseria meningitidis</i> Serogroup B" Antibodies against Strains of <i>Neisseria meningitidis</i> Serogroup B", <i>Infection and Immunity</i> , 69:3762-3771.
BL	MOLAGES et al., 1994, "Immune Response of Brazilian Children to a <i>Neisseria meningitidis</i> Serogroup B Outer Membrane Protein Vaccine; Comparison with Efficacy", <i>Infection and Immunity</i> , 62: 4419-4424.
BM	PIZZA et al. 2000 "Identification of Vaccine Candidates Against Serogroup B <i>Meningococcus</i> by Whole-Genome Sequencing", <i>Science</i> 287:1816-1820.
BN	ROUPPE VAN DER VOORT et al., 2000, "Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys", <i>Vaccine</i> , 18:1334-1343.
BO	SACCHI et al., 1998, "Correlation between Serological and Sequencing Analyses of the PorB Outer Membrane Protein in the <i>Neisseria meningitidis</i> Serotyping System", <i>Clin. Diag. Lab. Immunol.</i> 5:348-354.
BP	SACCHI et al., 2000, "Diversity and Prevalence of PorA Types in <i>Neisseria meningitidis</i> Serogroup B in the United States", <i>Journal of Infectious Diseases</i> , 182:1169-1176.


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐



PTO/SB/08A (08-09)
Approved for use through 10/31/2002. OMB 0651-0037
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/917.222
		Filing Date	July 27, 2001
		First Named Inventor	Granoff et al.
		Group Art Unit	1645
		Examiner Name	N/A
Sheet 4 of 4	Attorney Docket Number	CHOR-001	

BQ	SAUKKONEN et al. 1988, "Monoclonal Antibodies to the Rough Lipopolysaccharide of <i>Neisseria meningitidis</i> Protect Infant Rats From Meningococcal Infection" <i>Journal of Infectious Diseases</i> , 158: 209-212.
BR	SHAO-QING, et al., 1981, "Three new serogroups of <i>Neisseria meningitidis</i> ", <i>J. Biol. Stand.</i> 9: 307-315.
BS	SLATERUS, K. W., 1961, Ant. V. Leeuwenhoek, "Types of Meningococcal Isolated from Carriers and Patients in a Non-Epidemic Period in the Netherlands", <i>J. Microbiol. Serol.</i> 29: 265-271
BT	STEPHENS et al. 1991, "Insertion of Tn916 in <i>Neisseria meningitidis</i> Resulting in Loss of Group B Capsular Polysaccharide", <i>Infection and Immunity</i> , 59: 4097-4107
BU	TAPPERO et al., 1999, "Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines", <i>JAMA</i> 281:1520-1572.
BV	WYLE et al., 1972, "Immunologic Response of Man to Group B Meningococcal Polysaccharide Vaccines", <i>J Infect. Dis.</i> 126: 514-522.
BW	ZOLLINGER, et al., 1979, "Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in Man", <i>J Clin. Invest.</i> 63: 836-848.
BX	NAESS, et al. 1998, "Human T-Cell Response after Vaccination with the Norwegian Group B Meningococcal Outer Membrane Vesicle Vaccine" <i>Infection and Immunity</i> , Vol. 66(3): 959-965.
BY	HANEBERG et al. 1998, "Intranasal Administration of a Meningococcal Outer Membrane Vesicle Vaccine Induces Persistent Local Mucosal Antibodies and Serum Antibodies with Strong Bactericidal Activity in Humans", <i>Infection and Immunity</i> , Vol. 66(4): 1334-1341.
BZ	WEDEGE et al. 1998, "Immune Response against Major Outer Membrane Antigens of <i>Neisseria meningitidis</i> in Vaccines and Controls Contracted Meningococcal Disease during the Norwegian Serogroup B Protection Trial", <i>Infection and Immunity</i> , Vol. 66(7): 3223-3231.
CA	LEHMANN et al. 1999, "Human Opsonins Induced during Meningococcal Disease Recognize Outer Membrane Proteins PorA and PorB", <i>Infection and Immunity</i> , Vol. 67(5):2552-2560.
CB	ROSENQVIST et al. "Human Antibody Responses to Meningococcal Outer Membrane Antigens after three Doses of the Norwegian Group B Meningococcal Vaccine", <i>Infection and Immunity</i> , Vol. 63(12): 46-42-4652.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.